Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

Dow Jones01-27

0930 GMT - Roche Holding's results from a midstage study of obesity drug candidate CT-388 points to a competitive efficacy profile relative to Eli Lilly's Zepbound, but more data will be needed to make the comparison more accurate, J.P. Morgan analysts say in a research note. At 48 weeks, participants on the highest dose of CT-388 achieved a 22.5% weight loss when adjusting for placebo, while a separate Zepbound study showed a 17.9% reduction at that point, JPM says. Full data will be presented at an upcoming medical conference, and data on the baseline characteristics of the patients in the trial as well as the level of placebo weight loss will be key, according to JPM. Roche shares rise 0.6%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

January 27, 2026 04:30 ET (09:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment